Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels By Reuters
[ad_1] (Reuters) -Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol...
Pro Research: Wall Street dives into CRISPR Therapeutics’ gene editing future By Investing.com
[ad_1] © Reuters Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy...
What happens when a $2 million gene therapy is not enough By Reuters
[ad_1] 5/5 © Reuters. Elizabeth Kutschke spends time at the park with her 2-year-old son, Ben, who was diagnosed with spinal muscular atrophy, an inherited...
U.S. FDA approves bluebird bio’s gene therapy for a rare neurological disorder By Reuters
[ad_1] © Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020....